The common stock offering was increased to $100M and priced below last closing price of $22.16. Jefferies, Evercore ISI, Citi and Guggenheim are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Closing Bell Movers: Argan jumps 10% on earnings beat
- Zenas announces common stock, convertible senior notes offerings
- Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
- Zenas BioPharma price target raised to $55 from $45 at Guggenheim
- Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties